MRK - Organon reaffirms full year 2021 revenue guidance

In its first earnings report as a separately traded company from Merck (MRK), Organon (OGN) reiterated a forecast made in early May that its sees full year 2021 revenue of between $6.1B and $6.4B.The company also sees adjusted EBITDA margin in a range of 36% to 38%.The revenue forecast, however, still comes in below the $6.6B the women's health company earned last year.Organon reported Q1 GAAP EPS of $1.58. Because Organon shares only began trading on June 3, Q1 results are based on when it was a division of Merck.Organon shares are up 1.5% to $30.43 in morning trading.

For further details see:

Organon reaffirms full year 2021 revenue guidance